|
|
|
|
Federal Probe Finds Problems With Chelation Study
The study is testing chelation - infusions of a drug that in this case has been removed from the market for safety concerns.A different type of chelation is used to treat lead poisoning. Findings from the investigation were revealed...
|
|
|
Health Highlights: June 10, 2009
Here are some of the latest health and medical news developments, compiled by editors of HealthDay: A $30 million U.S.study of an alternative therapy called chelation has resumed enrolling volunteers with a history of heart attack,...
|
|
|
Alternative heart disease treatment probed
Heart attack survivors are again being enrolled in a controversial federal study of an alternative treatment while the government investigates whether they were told enough about possible health risks.The $30 million study, with 1,500...
|
|
|
Feds To Probe Study Of Alternative Heart Disease Treatment
Government investigators are again turning to heart attack survivors, enrolling them in a controversial new study of an alternative treatment of high dose vitamin supplements and chelation, a lead poisoning treatment that has not been proven...
|
|
|
Shire Presented Results Of A New Database Analysis On Lialda(R) (Mesalamine) And Other 5-ASAs For Ulcerative C
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented the results of a 5-aminosalicylic acid (5-ASA) persistency analysis entitled, 'Twelve-month Persistence with 5-aminosalicylic Acid Therapy:...
|
|
|
Shire plc Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerati
CHICAGO, June 1 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company, presented the results of a 5-aminosalicylic acid (5-ASA) persistency analysis entitled, 'Twelve-month Persistence with 5-aminosalicylic...
|
|
|
Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative C
CHICAGO, June 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented the results of a 5-aminosalicylic acid (5-ASA) persistency analysis entitled, 'Twelve-month Persistence...
|
|
|
Effect of White Mineral Trioxide Aggregate Mixed With Disodium Hydrogen Phosphate on Inflammatory Cells
Today in Endodontics...Effect of White Mineral Trioxide Aggregate Mixed With Disodium Hydrogen Phosphate on Inflammatory Cells.
|
|
|
Salix Pharmaceuticals Announces 1Q2009 Financial Results Conference Call and Webcast
RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd.(NASDAQ:SLXP - News) today announced that the Company will report first quarter 2009 financial results following the close of the U.S. financial markets on Tuesday, May 5, 2009....
|
|
|
Salix Pharmaceuticals Announces 1Q2009 Financial Results Conference Call and Webcast
Company Website: http:www.salix.comRALEIGH, N.C.-- (Business Wire) Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report first quarter 2009 financial results following the close of the U.S. financial...
|
